



# Zai Lab Announces Strategic Partnership, Exclusive Worldwide License Agreement With MediLink Therapeutics

May 12, 2023

**Palo Alto – May 12, 2023** – Cooley advised Zai Lab, a research-based commercial-stage biopharmaceutical company, on its strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics, as part of Zai Lab's efforts to build its portfolio of potential first- and/or best-in-class antibody-drug conjugate (ADC) products. Partner Lila Hope led the Cooley team.

The agreement will grant Zai Lab full responsibility for all development and commercialization activities globally of MediLink's YL212, a novel delta-like ligand 3 (DLL3) ADC program discovered by using MediLink's proprietary TAMLIN platform, which leverages the tumor microenvironment to overcome challenges in current ADC drugs.

Based in China and the US, Zai Lab is focused on discovering, developing and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases and neuroscience.

## About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our [AI Principles](#), may be considered Attorney Advertising and is subject to our [legal notices](#).

---

## Key Contacts

|                             |  |
|-----------------------------|--|
| Lila Hope<br>Palo Alto      | lhope@cooley.com<br>+1 650 843 5735    |
| Bin Wang<br>Palo Alto       | bwang@cooley.com<br>+1 650 843 5032    |
| Freddy Yip<br>Hong Kong     | fyip@cooley.com<br>+852 3758 1235      |
| Jameson Davis<br>Boston     | jdavis@cooley.com<br>+1 617 937 2380   |
| Amanda Pacheco<br>Palo Alto | apacheco@cooley.com<br>+1 650 843 5957 |

---

This information is a general description of the law; it is not intended to provide specific legal advice nor is it intended to create an attorney-client relationship with Cooley LLP. Before taking any action on this information you should seek professional counsel.

Copyright © 2023 Cooley LLP, 3175 Hanover Street, Palo Alto, CA 94304; Cooley (UK) LLP, 22 Bishopsgate, London, UK EC2N 4BQ. Permission is granted to make and redistribute, without charge, copies of this entire document provided that such copies are complete and unaltered and identify Cooley LLP as the author. All other rights reserved.